Heart failure & cardiomyopathies
EVOLUTION-HF DEallEF: A Non-Interventional Study of Patients with Heart Failure Initiated On Dapagliflozin: Study Design
Study context
- Population
- Patients ≥18 years of age with heart failure (HF) in Germany who started dapagliflozin treatment 14–90 days prior to enrolment according to the local product label; excluded: previous SGLT2i treatment (including dapagliflozin), type 1 diabetes, and hypersensitivity to dapagliflozin or its excipientsplanned enrolment (700 evaluable)
- Participants
- 1,000 patients
- Planned comparison
- HFpEF vs HFmrEF vs HFrEF
- Primary endpoint
- Demographic and clinical characterization of patients and the assessment of treatment patterns of dapagliflozin, other HF medications, and glucose-lowering medications
- Follow-up
- Every 3 months for up to 12 months
Methodological detailsmultinational umbrella EVOLUTION-HF study protocol
- Multinational umbrella EVOLUTION-HF study protocol
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Study conduct
- First patient included in April 2024; currently open for enrolment
Original publication
EVOLUTION-HF DEallEF: A Non-Interventional Study of Patients with Heart Failure Initiated On Dapagliflozin: Study Design. ESC Heart Fail. Published 27 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →